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Introduction {#sec1}
============

*Bifidobacterium* represents a keystone member of the early life gut microbiota ([@bib1]; [@bib43]; [@bib5]). Certain species and strains are found at high levels in vaginally delivered breast-fed infants including *Bifidobacterium longum* subsp. *infantis*, *B*. *longum* subsp. *longum*, *Bifidobacterium bifidum*, *Bifidobacterium pseudocatenulatum,* and *Bifidobacterium breve* ([@bib7]; [@bib35]; [@bib37]; [@bib60]). As a dominant member of the neonatal gut microbiota, *Bifidobacterium* is associated with metabolism of breast milk, modulation of host immune responses, and protection against infectious diseases ([@bib11]; [@bib33]; [@bib53]; [@bib30]; [@bib45]; [@bib2]; [@bib26]; [@bib50]). However, the mechanisms driving improved health outcomes during early life are largely underexplored and are likely strain dependent.

A key interface between *Bifidobacterium* and the host is the intestinal epithelial cell (IEC) barrier ([@bib61]; [@bib16]). Previous studies have indicated that certain strains of *Bifidobacterium* specifically modulate IEC responses during inflammatory insults, which may help protect from certain gut disorders ([@bib22]; [@bib58]; [@bib15]). In murine experimental models, previous work by our group has shown that infant-associated *B*. *breve* UCC2003 modulates cell death-related signaling molecules, which in turn reduces the number of apoptotic IECs ([@bib23]). This protection from pathological IEC shedding appeared to be via the *B*. *breve* exopolysaccharide (EPS) capsule and the host-immune adaptor protein MyD88. Another strain of *B*. *breve*, NumRes 204 (commercial strain) has also been shown to up-regulate the tight junction (TJ) proteins Claudin 4 and Occludin in a mouse colitis model ([@bib65]; [@bib48]).

Many of the studies to date have focused on the role of *Bifidobacterium* and modulation of IECs in the context of acute or chronic gut inflammation, with expression profiling limited to specific immune or apoptosis signaling targets ([@bib49], [@bib52]; [@bib34]; [@bib22]). As many of these studies have involved pre-colonization of the gut with *Bifidobacterium* strains, followed by inflammatory insult, this suggests that initial priming during normal "healthy" conditions may modulate subsequent protective responses. Furthermore, these studies have often been performed in adult mice rather than exploring effects during the early life developmental window, where *Bifidobacterium* effects are expected to be most pronounced. Previous work has indicated that there is significant modulation of the neonatal IEC transcriptome in response to gut microbiota colonization, but to date no studies have probed how particular early life-associated microbiota members, like *Bifidobacterium,* may modulate neonatal IEC responses ([@bib44]). Thus, to understand if and how *Bifidobacterium* may modulate IEC homeostasis during the early life developmental window, we administered *B*. *breve* UCC2003 to neonatal mice and profiled transcriptional responses in isolated small intestine IECs using global RNA sequencing (RNA-seq). Our analysis indicated whole-scale changes in the transcriptional program of IECs (∼4,000 significantly up-regulated genes) that appear to be linked to cell differentiation/proliferation and immune development. Notably the stem cell compartment of IECs seemed to elicit the strongest gene signature. These data highlight the role of *B*. *breve* UCC2003 in driving early life epithelial cell differentiation and maturation, impacting intestinal integrity and immune functions, which provides a mechanistic basis for understanding associated health-promoting effects.

Results {#sec2}
=======

To examine the effects of *B*. *breve* UCC2003 on the transcriptional profiles of host IECs under homeostatic conditions, we extracted RNA from isolated IECs of healthy 2-week-old neonatal mice (control group) and mice gavaged with *B*. *breve* UCC2003 for three consecutive days (*n* = 5 per group). Isolated RNAs from IECs were subjected to RNA-seq to determine global mRNA expression ([Figure 1](#fig1){ref-type="fig"}). Subsequently, Differential Gene Expression analysis was performed to understand *B*. *breve*-associated gene regulation.Figure 1Schematic Representation of the Study Design and *In Silico* Analysis Workflow

Minimal Impact of *B*. *breve* UCC2003 on the Wider Neonatal Gut Microbiota {#sec2.1}
---------------------------------------------------------------------------

Initially, we examined for the presence of *B*. *breve* UCC2003 in the gut microbiome and impact on the wider microbiota using culture and 16S rRNA microbiota profiling approaches ([Figures 2](#fig2){ref-type="fig"}A and 2B). We observed high levels of *B*. *breve* UCC2003 across the 4 days in fecal samples, with higher levels of viable *B*. *breve* UCC2003 within the colon (∼10^8^ CFU/g \[colony-forming unit\]), when compared with the small intestine (∼10^5^ CFU/g; [Figure 2](#fig2){ref-type="fig"}B). Based on 16S rRNA analysis, relative abundance of *Bifidobacterium* increased significantly in the UCC2003 group (p = 0.012) following bacterial administration, whereas the control group displayed very low relative *Bifidobacterium* abundance (∼0.01%; [Figure 2](#fig2){ref-type="fig"}C). Principal-component analysis (PCA) on gut microbiota profiles (control versus UCC2003) showed a distinct change in microbial community composition in the UCC2003 group primarily driven by increased relative abundance of *Bifidobacterium*, which may also correlate with increased overall microbial diversity in the UCC2003 group ([Figures 2](#fig2){ref-type="fig"}D and 2E). Linear Discriminant Analysis also indicated that *Bifidobacterium* was uniquely enriched in UCC2003 group, and that microbiota members with low relative abundance (\<2%) such as *Streptococcus*, *Ruminococcus*, *Prevotella,* and *Coprococcus* were significantly lower ([Figures 2](#fig2){ref-type="fig"}F and 2G). Overall, administration of *B*. *breve* UCC2003 appeared to minimally impact the wider gut microbiota, without significantly altering relative abundance of other major resident taxa including *Lactobacillus*, *Bacteroides,* and *Blautia* compared with the control group.Figure 216S rRNA Amplicon Sequencing Analysis of Murine Intestinal Microbiota(A) Genus-level 16S rRNA gene profiling of mice gut microbiota on day 4 (control versus UCC2003).(B) Dynamics of *B*. *breve* UCC2003 load (CFU/g) from day 1 (before *B*. *breve* administration) through day 4. *B. breve* was present in intestines throughout (small intestines and colon; on day 4). ND, non-detectable. Data are represented as mean ± SD.(C) Relative abundance of genus *Bifidobacterium* in UCC2003 group is significantly increased.(D) Principal-component analysis on mice gut microbiota (control versus UCC2003 based on genus-level metataxonomics).(E) Shannon diversity index on mice gut microbiota (control versus UCC2003). Data are represented as mean ± SD. Significance test: t test (∗p \< 0.05; two-sided).(F) Linear Discriminant Analysis (LDA) showing enriched taxa in each group (control versus UCC2003).(G) Relative abundance comparison of all genera. ∗p \< 0.05 (LDA).

Impact of *B*. *breve* UCC2003 on the Neonatal Intestinal Epithelial Transcriptome {#sec2.2}
----------------------------------------------------------------------------------

To understand the distribution of samples based on IEC gene expression profiles we performed PCA analysis ([Figure 3](#fig3){ref-type="fig"}A; [Table S1](#mmc2){ref-type="supplementary-material"}). All samples clustered according to group (control versus UCC2003), suggesting a significant impact of *B*. *breve* UCC2003 on gene expression profiles, with distance-wise clustering (Jensen-Shannon) also supporting separation of experimental groups ([Figure 3](#fig3){ref-type="fig"}B). To define differentially expressed genes (DEGs), we employed a filter of absolute log~2~fold change (LFC) \> 1.0 (with adjusted p \< 0.05), which equates to a minimum 2-fold change in gene expression ([Figures 3](#fig3){ref-type="fig"}C--3E; [Table S2](#mmc3){ref-type="supplementary-material"}). After analysis, a total of 3,996 DEGs were significantly up-regulated, whereas 465 genes were significantly down-regulated in *B*. *breve* UCC2003-supplemented animals when compared with controls ([Figures 3](#fig3){ref-type="fig"}C and [4](#fig4){ref-type="fig"}A). Notably, we also performed the same experimental protocol on healthy mice aged 10--12 weeks and did not observe any significant DEGs, suggesting that *B*. *breve* UCC2003 modulation of IECs is strongest within the early life window under homeostatic conditions.Figure 3RNA-Seq Analysis and Statistics(A) Principal-component analysis showing distinct overall gene expression profiles across all individual samples based on 12,965 highly expressed genes. See also [Table S1](#mmc2){ref-type="supplementary-material"}.(B) Clustering of individual RNA-seq samples based on Jensen-Shannon distance. Distinct gene expression profiles were demonstrated between these two groups of samples (control versus UCC2003).(C) Total number of differentially expressed genes (DEGs) in UCC2003 group.(D) Volcano plot of global gene expression. Up-regulated DEGs are labeled as red dots, whereas down-regulated DEGs are labeled in blue.(E) MA plot of global gene expression (plot of log-intensity ratios \[M-values\] versus log-intensity averages \[A-values\]).Figure 4Gene Expression Analysis(A) Heatmap comparison of gene expression profiles of 4,461 DEGs (control versus UCC2003). See also [Table S2](#mmc3){ref-type="supplementary-material"}.(B) Top 20 DEGs ranked by false discovery rate -adjusted p values (q values).(C) Top 20 up-regulated DEGs ranked by log~2~FC (fold change) values.(D) Top 20 down-regulated DEGs ranked by log~2~FC values.(E) Expression of epithelial integrity associated genes in UCC2003 group (q \< 0.05).(F) Expression of integrin-associated genes in UCC2003 group. Gray dotted lines in the bar charts indicate the threshold of absolute log~2~FC \> 1.0. Data are represented as mean ± SE.

To determine the functional role of DEGs, we examined the most significantly regulated genes ranked by false discovery rate-adjusted p values (or, *q* values). We first looked at the top 20 up-regulated DEGs in the *B*. *breve* UCC2003 experimental group ([Figure 4](#fig4){ref-type="fig"}B). Most genes annotated with known biological processes had cell differentiation and cell component organization functions including *Ccnb1ip1*, *Hist1h4b*, *Vps13b,* and *Fgd4* (annotated in the PANTHER Gene Ontology \[GO\] Slim resource). Two genes were involved in cell death and immune system processes, namely, *Naip6* and *Gm20594* ([Table S3](#mmc1){ref-type="supplementary-material"}). When we ranked the top-regulated genes using LFC, we observed increased expression of *Creb5*, which is involved in the regulation of neuropeptide transcription (cAMP response element-binding protein; CREB) ([Figure 4](#fig4){ref-type="fig"}C). CREB is also known to regulate circadian rhythm, and we also identified additional circadian-clock-related genes that were significantly up-regulated including *Per2* and *Per3*. We noted that several top down-regulated DEGs were annotated as genes involved in metal binding, or metal-related genes including *Mt1*, *Mt2*, *Hba-a1*, *Hbb-bt,* and *Ftl1-ps1* ([Figure 4](#fig4){ref-type="fig"}D; [Table S4](#mmc1){ref-type="supplementary-material"}).

Regulation of Intestinal Epithelial Barrier-Associated Genes {#sec2.3}
------------------------------------------------------------

As *B*. *breve* strains have been previously shown to modulate certain TJ/barrier-related proteins, we next investigated DEGs associated with intestinal epithelial barrier development/intestinal structural organization ([Figure 4](#fig4){ref-type="fig"}E). Several TJ structural-associated DEGs were observed, including Claudin-encoding gene *Cldn34c1* (LFC 3.14), Junction Adhesion Molecules-encoding genes *Jam2* (LFC 2.9), and TJ protein (also called Zonula Occludens protein; ZO)-encoding gene *Tjp1* (LFC 1.49). Genes that encode integrins (involved in regulation of intracellular cytoskeleton) also exhibited a trend of increased expression (13/14; 92.8%). Both Piezo genes, which assist in TJ organization, *Piezo1* (LFC 1.25) and *Piezo2* (LFC 1.9), were significantly up-regulated in the *B*. *breve* UCC2003-treated group.

Over 90% cadherins, proteins associated with the assembly of adherens junctions ([Figure 4](#fig4){ref-type="fig"}E), were up-regulated, including *Pcdhb14* (LFC 2.8), *Pcdhgb4* (LFC 2.7), *Pcdh8* (LFC 1.3), *Fat1* (LFC 1.5), and *Dsg2* (LFC 1.1). Interestingly, several genes (4/7; 57.1%) involved in mucous layer generation were significantly up-regulated in the UCC2003 experimental group, including *Muc2* (LFC 2.2), *Muc6* (LFC 3.7), *Muc5b* (LFC 2.9), and *Muc4* (LFC 1.24). Genes *Gja1* (LFC 3.59) and *Gjb8* (LFC 2.63) that encode gap junction proteins were also up-regulated. In addition, we also investigated the differential expression of genes associated with integrin assembly and downstream integrin signaling pathways ([Figure 4](#fig4){ref-type="fig"}F). Over 70% (16/21) of these genes were up-regulated, with 52.3% (11/21) significantly increased in gene expression in the UCC2003 group (LFC \>1.0).

We observed increased expression of genes associated with IEC barrier development including cadherins, gap junctions, integrins, mucous layer-associated genes, and several key TJ proteins. These strongly induced gene expression profiles suggest that *B*. *breve* UCC2003 is involved in enhancing epithelial barrier development in neonates.

Modulation of Cell Maturation Processes {#sec2.4}
---------------------------------------

We next sought to understand the biological functions of up-regulated DEGs by employing PANTHER GO-Slim functional assignment and process/pathway enrichment analysis (see [Figure S1](#mmc1){ref-type="supplementary-material"}; [Tables S5](#mmc1){ref-type="supplementary-material"} and [S6](#mmc1){ref-type="supplementary-material"}). DEGs were predominantly involved in general biological processes including cellular process (901 genes) and metabolic process (597 genes; [Table S7](#mmc1){ref-type="supplementary-material"}). At the molecular function level, DEGs were primarily assigned to binding (868 genes) and catalytic activity (671 genes; [Table S8](#mmc1){ref-type="supplementary-material"}), with Olfactory Signaling Pathway and Cell Cycle (biological) pathways also found to be enriched ([Table S9](#mmc1){ref-type="supplementary-material"}).

To delve further into the data, we constructed a signaling network based on up-regulated DEGs (*n* = 3,996) with the aim of identifying specific gene networks involved in important signaling pathways ([Figure 5](#fig5){ref-type="fig"}A). Overall, 1,491 DEGs were successfully mapped (37.3%) to a signaling network that comprised 8,180 genes. Four individual clusters of genes were detected, with functional assignment and pathway analysis implemented on these clusters ([Figure 5](#fig5){ref-type="fig"}A). All gene clusters were associated with cell differentiation and maturation, with cluster 1 (68 genes) linked specifically with DNA replication and transcription, cluster 2 (26 genes) with cell growth and immunity, cluster 3 (11 genes) with cell replication, and cluster 4 (72 genes) related to cell cycle and cell division ([Table S10](#mmc4){ref-type="supplementary-material"}).Figure 5Signaling Network Analysis, IEC Subtyping, and Key Regulator Analysis(A) Cluster analysis of signaling network for significantly up-regulated genes (*n* = 3,996). Representative enriched pathways (Reactome) and GO terms (Biological Process) identified in each individual cluster were listed alongside. See also [Table S10](#mmc4){ref-type="supplementary-material"}.(B) Heat plot showing percentage of cell type signature genes in DEG and expressed genes (both control and UCC2003 groups). All expressed genes are well represented in IEC cell type signature genes.(C) Cell type analysis on IEC DEGs using known cell-specific signature genes. Stem cells were statistically over-represented in DEGs. ∗p \< 0.05. See also [Table S11](#mmc5){ref-type="supplementary-material"}.(D) Key regulators of stem cell DEGs.

Intestinal Cell Type Analysis on DEGs Identifies Significant Enrichment of Epithelial Stem Cells {#sec2.5}
------------------------------------------------------------------------------------------------

IECs include several absorptive and secretory cell types, namely, enterocytes, Paneth cells, goblet cells, enteroendocrine cells, tuft cells, and stem cells. As these cells perform different functions in the gut, it was important to understand whether *B*. *breve* UCC2003 had a cell type-specific effect on the intestinal epithelium. Using known cell type-specific gene markers ([@bib18]), we identified cell type gene signatures modulated within the UCC2003 group ([Figures 5](#fig5){ref-type="fig"}B and 5C). Importantly, all cell type markers were well represented in the expressed genes of the whole IEC transcriptomics data from both groups (control + UCC2003), thus validating the presence of all IEC types in our study data ([Figure 5](#fig5){ref-type="fig"}B). Cell type analysis of genes differentially expressed after *B*. *breve* UCC2003 supplementation revealed that stem cell marker genes were significantly enriched (30%; p \< 0.05) among the six IEC types ([Table S11](#mmc5){ref-type="supplementary-material"}). Signatures of other cell types were also present (linking to marker genes in the DEG list) but not significantly overrepresented: tuft cells (22%), enteroendocrine cells (18%), goblet cells (15%), Paneth cells (15%), and enterocytes (13%; [Figure 5](#fig5){ref-type="fig"}C). These data indicated that intestinal epithelial stem cells, cells primarily involved in cell differentiation, were the primary cell type whose numbers and transcriptomic program were regulated by *B*. *breve* UCC2003.

Further investigation of this stem cell signature revealed that of the 37 differentially expressed marker genes, 35 are up-regulated in the presence of *B*. *breve* UCC2003. This indicates an increase in the quantity of stem cells or semi-differentiated cells in the epithelium, consistent with the overrepresentation of cell cycle- and DNA replication-associated genes observed in the whole differential expression dataset. Functional analysis of the 37 stem cell signature genes revealed only one overrepresented process---Regulation of Frizzled by ubiquitination (p \< 0.05), which is a subprocess of WNT signaling. WNT signaling is important in maintaining the undifferentiated state of stem cells ([@bib40]).

Finally, we employed a network approach to predict key transcription factor (TF) regulators of the differentially expressed stem cell marker genes, through which *B*. *breve* UCC2003 may be acting ([Figure 5](#fig5){ref-type="fig"}D). Using the TF-target gene database, DoRothEA, we identified expressed TFs known to regulate these genes ([@bib14]; [@bib21]). Five genes had no known and expressed regulator, and thus were excluded. Hypergeometric significance testing was used to identify which of these TFs are the most influential (see [Methods](#sec4){ref-type="sec"} for details). This analysis identified 32 TF regulators ([Figure 5](#fig5){ref-type="fig"}D). Of these regulators, 12 were differentially expressed in the IEC dataset (all up-regulated): *Fos*, *Gabpa*, *Rcor1*, *Arid2*, *Tead1*, *Mybl2*, *Mef2a*, *Ahr*, *Pgr*, *Kmt2a*, *Ncoa2,* and *Tcf12*. Functional analysis of all the TF regulators and their targeted genes together, revealed overrepresented functions relating to WNT signaling, histone methylation for self-renewal and proliferation of hematopoietic stem cells, and nuclear receptor (incl. estrogen) signaling ([Table S12](#mmc1){ref-type="supplementary-material"}). These data indicate that *B*. *breve* UCC2003 directly affects key transcriptomic programs that regulate specific signaling processes, particularly within stem cells.

Discussion {#sec3}
==========

The early life developmental window represents a crucial time for microbe-host interactions that impacts health both in the short and longer term. Understanding how specific microbiota members modulate host responses in pre-clinical models may help the design and development of next-stage targeted microbiota therapies in humans. Here we investigated how *B*. *breve* UCC2003 induces genome-wide transcriptomic changes in small intestine IECs of neonatal mice. We observed that *B*. *breve* had a global impact on the IEC transcriptome, evidenced by the large number of significantly up-regulated genes and pathways related to cell differentiation and cell proliferation, including genes associated with epithelial barrier function. We propose that *B*. *breve* may act as a key early life microbiota member driving fundamental cellular responses in murine IECs, particularly within the stem cell compartment, and thus drives epithelial barrier development and maintenance during neonatal life stages. However, further clinical studies would be required to determine if our findings extrapolate to the human setting.

*B*. *breve* is known to confer beneficial effect on gut health; however, our knowledge related to the mechanisms underlying these responses is limited. Most studies have focused on targeted immune cells or pathways (during disease and/or inflammation), and to our knowledge no studies have probed global transcriptomic changes within IECs, the frontline physical barrier between bacteria and host ([@bib63]; [@bib13]). Our presented findings in a pre-clinical model, namely, ∼4,000 up-regulated DEGs and ∼450 down-regulated DEGs within the *B*. *breve* group, indicate that this *Bifidobacterium* strain modulates whole-scale changes within this critical single-cell layer. Notably, we also examined how *B*. *breve* modulates adult IEC responses; however, we did not observe any significantly differentially regulated genes when compared with control animals. The striking differences in DEGs between these two life points indicate that *B*. *breve* modulation of IECs is limited to the neonatal window. Dominance of *Bifidobacterium* in early life (including strains of *B*. *breve*) overlaps with the development and maturation of many host responses, including epithelial barrier integrity. Therefore, presence of these strains would be expected to play an over-sized role in this initial homeostatic priming, which may afford protection against inflammatory insults in later life, as has been shown previously in a mouse model of pathological epithelial cell shedding ([@bib23]). Further clinical studies would be required to probe these findings in detail to determine their importance during healthy infant development.

Exploring the murine transcriptional responses in more detail revealed that expressions of key genes associated with formation of epithelial barrier components were up-regulated, including major cell junction protein-encoding genes (75%; 42/56 genes). More specifically, several integrin-associated genes were up-regulated in the presence of UCC2003. Integrins facilitate cell-cell and cell-extracellular matrix adhesion and binding and assembly of the fibronectin matrix that is pivotal for cell migration and cell differentiation ([@bib19]; [@bib51]; [@bib36]). Integrins also play an important role in downstream intracellular signaling that controls cell differentiation, proliferation, and cell survival, including the Raf-MEK-ERK signaling pathway (we also observed enrichment of genes involved in this pathway) ([@bib3]; [@bib32]). Another key intestinal barrier component is represented by TJs, linking complexes between intercellular spaces, and comprise transmembrane proteins including occludins, claudins, zona occludens, and junctional adhesion molecules ([@bib8]; [@bib16]). Dysfunctional TJ may lead to a "leaky" gut, which is characteristic of numerous intestinal disorders including inflammatory bowel diseases ([@bib29]). Notably, previous work has suggested early life microbiota disruptions (via antibiotic usage) and reductions in *Bifidobacterium* are correlated with increased risk and/or symptoms of ulcerative colitis and Crohn\'s disease ([@bib28]; [@bib20]; [@bib10]; [@bib54]; [@bib39]). Several clinical studies have indicated that supplementation with certain *Bifidobacterium* strains positively modulate gastrointestinal symptoms of patients, which is corrected with reductions of inflammatory markers in colonic IEC-containing biopsies; however, *B*. *breve* UCC2003 has not been used clinically in this patient setting ([@bib12]; [@bib59]). Similar findings have also been reported in different animal models of intestinal inflammation ([@bib46]; [@bib15]; [@bib66]). A wide range of TJ-related genes were up-regulated after UCC2003 supplementation, particularly *Tjp1* (that encodes ZO-1), *Jam2,* and *Claudin34c1*, with a previous study indicating that other *Bifidobacterium* species (i.e., *B*. *bifidum*) also modulate TJ expression via ZO-1 ([@bib6]). These data indicated that specific strains of *Bifidobacterium* may modulate key barrier integrity systems during the neonatal period, and therefore absence of this key initial bacterial-host cross talk may correlate with increased risk of chronic intestinal disorders in later life ([@bib54]). Intestinal mucus, encoded by *Muc* genes (up-regulated due to *B*. *breve* UCC2003 in this study), plays a crucial role in colonic protection via formation of a physical barrier between the gut lumen and IECs, and deficiencies in MUC-2 have been linked with experimental colitis and increased inflammation in patients with inflammatory bowel disease ([@bib56], [@bib64]). We have also observed that *B*. *breve* UCC2003 significantly increases goblet cell numbers and mucus production (in gnotobiotic and SPF mice; data not shown). Although the mucus layer may impact direct *Bifidobacterium*-IEC interactions, previous studies have indicated that *B*. *breve* UCC2003 surface molecules, such as EPS and the Tad pilus, may modulate IEC function via signaling through Toll-like receptors (TLRs) ([@bib41]; [@bib23]). Moreover, bifidobacterial metabolites, such as short-chain fatty acids may also act to modulate the IEC transcriptome, with previous studies indicating enhanced expression of TJs and cadherins via acetate ([@bib22]; [@bib33]; [@bib9]; [@bib31]).

Further network and functional analysis indicated that clusters of up-regulated DEGs were associated with cell maturation and cell differentiation (as confirmed by cell type-specific analysis), suggesting that neonatal *B*. *breve* exposure positively modulates IEC cell differentiation, growth, and maturation. Somewhat surprisingly, we did not observe the same type of striking responses in immune pathways, which may be masked by the sheer number of DEGs involved in cellular differentiation and processes. However, pathways such as TLR1 and TLR2 pathways do appear to be enriched (cluster 2 of signaling network analysis). This may link to previous work indicating that the UCC2003 EPS signals via TLR2 to induce MyD88 signaling cascades to protect IECs during intestinal inflammation ([@bib23]). *B*. *breve* M-16V was also shown to interact with TLR2 to up-regulate ubiquitin-editing enzyme A20 expression that correlated with increased tolerance to a TLR4 cascade in porcine IECs, further supporting the involvement of *B*. *breve* in programming key host immunoregulation receptors ([@bib62]).

Cell type-specific analysis of DEGs revealed stem cells as the IEC type most affected by *B*. *breve*, with absorptive enterocytes least affected despite being most accessible to bacteria in the gut. It could be hypothesized that *B*. *breve* or their secreted metabolites may reach the crypts of the small intestinal epithelium. This has been previously suggested by *in situ* hybridization histology *in vivo* and by *Bifidobacterium*-conditioned media altering the expression of hundreds of host epithelial genes linked to immune response, cell adhesion, cell cycle, and development in IECs *in vitro* ([@bib23]; [@bib17]). However, the direct impact of bifidobacterial-associated metabolites on these responses would require further studies to confirm metabolic activity of *B*. *breve* within the small intestine (via transcriptomics and metabolomics), although daily supplementation with live bacteria may also provide a source of these metabolites in our model. Interestingly, certain *Bifidobacterium* and *Lactobacillus* strains that have been heat killed have also been shown to induce host responses, indicating that surface structures alone may play a role in downstream effects ([@bib47]). All but two of the 37 differentially expressed stem cell marker genes were up-regulated in the presence of *B*. *breve* UCC2003, indicating an activating effect resulting in increased pluripotency of stem cells, increased quantity of stem cells, and/or an increased quantity of semi-differentiated cells. Single-cell sequencing of IECs could be used to further investigate this finding. Thirty-two TFs were predicted to regulate these stem cell signature genes, providing possible targets for future investigation of the mechanisms underlying these responses. Functional analysis of the stem cell signature genes and their regulators suggests that *B*. *breve* increases pluripotency of stem cells and/or semi-differentiated epithelial cells through WNT signaling and nuclear hormone signaling ([@bib27]). Furthermore, the overrepresentation of the process "RUNX1 regulates transcription of genes involved in differentiation of HSCs" indicates a possible role for histone methylation in response to *B*. *breve* UCC2003 ([@bib25]). Further determination of host and bacterial metabolome and proteome after *B*. *breve* exposure may allow identification of the specific underlying molecular mechanisms ([@bib17]).

In conclusion, *B*. *breve* UCC2003 plays a central role in orchestrating global neonatal IEC gene responses in a distinct manner as shown in our murine model, modulating genes involved in epithelial barrier development, and driving universal transcriptomic alteration that facilitates cell replication, differentiation, and growth, particularly within the stem cell compartment. This study enhances our overall understanding of the benefits of specific early life microbiota members in intestinal epithelium development, with prospective avenues to probe further health-promoting mechanisms of *Bifidobacterium* in humans. Further work exploring time-dependent transcriptional responses and impact of other *Bifidobacterium* species and strains (and use of mutants and transcriptionally active strains as positive controls), in tandem with metabolomic and proteomic approaches, is required to advance our understanding on the key host pathways and bifidobacterial molecules governing development and maturation of the intestinal barrier during the early life window. Nevertheless, further clinical studies would be essential to explore if these responses and findings are similar to those observed in humans.

Limitations of the Study {#sec3.1}
------------------------

As we only observed low relative abundance of *Bifidobacterium* in our control neonatal animals this may suggest that induction of responses may be linked to the introduction of a new microbiota member (i.e., *B*. *breve* UCC2003), therefore results should be carefully interpreted. However, we did not observe associated global transcriptional inflammatory immune changes that would be expected if this was the case, but rather global changes in barrier function transcripts and pathways. Furthermore, *Bifidobacterium* has previously been isolated from C57BL/6 mice (including from our mouse colony), and therefore appears to be a resident rodent gut microbiota member, although it is found at varying abundances in different animal units and suppliers ([@bib15]; [@bib24]). Indeed, one particular study has shown that high levels of resident *Bifidobacterium* in mice directly correlated with improved immune responses to cancer immunotherapies ([@bib57]). In addition, we did not explore if *B*. *breve* UCC2003 is potentially driving more nuanced microbe-microbe interactions, and that, indirectly, these may also be stimulating IEC responses. Therefore, further studies probing these aspects in more detail, and comparing other *Bifidobacterium* strains, to compare and contrast responses, would be of interest.

*B*. *breve* UCC2003 is a model strain that was previously isolated from the stool of a breast-fed infant ([@bib38], [@bib55]). Although a human-associated strain, it has not been used in clinical studies, so directly extrapolating to human-specific settings should be cautiously considered. Further large-scale clinical studies would be required to confirm any positive strain-level impacts; however, in-depth analysis of, e.g., small IECs would be unethical in a healthy infant cohort, which emphasizes the importance of preclinical models.

Previous studies have shown that this strain can efficiently colonize (long term) the mouse gastrointestinal tract; however, we could not confirm this in our short-term, daily supplementation study ([@bib4], [@bib42]). Therefore the IEC responses observed may occur as a result of transient interactions with *B*. *breve* UCC2003 as it passes through the small intestine. Nevertheless, although at lower levels (∼10^5^ CFU/g), we did observe viable *B*. *breve* UCC2003 in the small intestine, linking to our subsequent observations of significant impacts on the IEC transcriptome from this intestinal region.

Very-low-abundance microbiota members (\<2% relative abundance), including *Streptococcus*, *Ruminococcus*, *Prevotella*, and *Coprococcus,* were significantly reduced in relative abundance compared with controls, raising the question whether supplementation of *Bifidobacterium* could have reduced these taxa. Regrettably, we could not determine if this is a bifidobacterial effect due to the lack of longitudinal samples, and we did not quantify bacterial titers, which is an important consideration for future work. We also did not profile microbial community composition within the small intestines, which is known to differ from fecal samples.

Resource Availability {#sec3.2}
---------------------

### Lead Contact {#sec3.2.1}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Lindsay J. Hall (<Lindsay.Hall@quadram.ac.uk>).

### Materials Availability {#sec3.2.2}

This study did not generate new unique reagents.

### Data and Code Availability {#sec3.2.3}

The code generated for RNA-seq analysis during this study is available at GitHub <https://github.com/raymondkiu/Bifidobacterium-IEC-transcriptomics>. The accession number for the raw sequencing reads (both RNA-seq and 16S rRNA amplicon sequencing) reported in this paper is European Nucleotide Archive (ENA): PRJEB36661.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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